All In Biotech

Drug Trial Radar · NCT04065399

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

A Phase 1/2, Open-label, Dose-Escalation and Dose-Expansion Cohort Study of SNDX-5613 in Patients With Relapsed/Refractory Leukemias, Including Those Harboring an MLL/KMT2A Gene Rearrangement or Nucleophosmin 1 (NPM1) Mutation

Last checked: Nov 19, 2026Latest source record: Oct 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

447

Planned (sponsor's estimate)

Start

Nov 5, 2019

Primary completion

Dec 15, 2027

Study completion Dec 15, 2027

Sponsor

Lead sponsor
Syndax PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Aug 22, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 30 days
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase 1 dose escalation will determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of revumenib in participants with acute leukemia. In Phase 2, participants will be enrolled in 4 indication-specific expansion cohorts to determine the efficacy, short- and long-term safety, and tolerability of revumenib.

Conditions

  • Acute Myeloid Leukemia
  • Acute Lymphoblastic Leukemia
  • Mixed Lineage Acute Leukemia
  • Mixed Phenotype Acute Leukemia
  • Acute Leukemia of Ambiguous Lineage

Interventions

  • revumenibDrug

    revumenib orally

  • cobicistatDrug

    Phase 1 Arm C participants will receive 150 mg cobicistat daily.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with dose-limiting toxicities (DLTs) (Phase 1)Time frame: Approximately 1 year
  2. Number of participants with treatment-emergent adverse events (TEAEs) (Phase 1)Time frame: Approximately 1 year
  3. Cmax (Phase 1)Time frame: Approximately 1 year
  4. Tmax (Phase 1)Time frame: Approximately 1 year
  5. AUC0-t (Phase 1)Time frame: Approximately 1 year
  6. CR+CRh rate (Phase 2 [Cohorts 2A-2C])Time frame: Approximately 3 years
  7. Number of participants with TEAEs (Phase 2 [Cohorts 2A-2C])Time frame: Approximately 3 years
  8. Cmax (Phase 2 [Cohort 2D])Time frame: Approximately 3 years
  9. AUC0-tau (Phase 2 [Cohort 2D])Time frame: Approximately 3 years

Locations

57 sites in 11 countries. Site status is shown where the registry gives one.

  • City of Hope Comprehensive Cancer Center

    Duarte, California · Active not recruiting

  • University Of California Care Medical Group - Norris Comprehensive Cancer Center And Hospital

    Los Angeles, California · Completed

  • Stanford Cancer Institute

    Palo Alto, California · Active not recruiting

  • University of Colorado

    Aurora, Colorado · Recruiting

  • Florida Cancer Specialists and Research Institute

    Sarasota, Florida · Active not recruiting

  • Moffitt Cancer Center

    Tampa, Florida · Completed

  • Emory Winship Cancer Institute

    Atlanta, Georgia · Recruiting

  • Children's Healthcare of Atlanta

    Atlanta, Georgia · Completed

  • The University of Chicago Medical Center

    Chicago, Illinois · Recruiting

  • University of Iowa Hospital

    Iowa City, Iowa · Recruiting

  • Dana Farber Cancer Institute

    Boston, Massachusetts · Active not recruiting

  • Washington University in St. Louis School of Medicine

    St Louis, Missouri · Recruiting

  • Hackensack University Medical Center

    Hackensack, New Jersey · Completed

  • Memorial Sloan Kettering Cancer Center

    New York, New York · Active not recruiting

  • Montefiore Medical Center

    New York, New York · Recruiting

  • Duke University Medical Center

    Durham, North Carolina · Recruiting

  • University of Cincinnati

    Cincinnati, Ohio · Completed

  • Ohio State University

    Columbus, Ohio · Recruiting

  • Oregon Health & Science University

    Portland, Oregon · Recruiting

  • University of Pennsylvania

    Philadelphia, Pennsylvania · Recruiting

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas · Active not recruiting

  • Huntsman Cancer Institute at the University of Utah

    Salt Lake City, Utah · Completed

  • Alfred Hospital

    Melbourne, Australia · Recruiting

  • Sir Charles Gairdner Hospital

    Nedlands, Australia · Recruiting

  • Royal North Shore Hospital

    Saint Leonards, Australia · Recruiting

  • Peter MacCallum Cancer Centre (PMCC)

    Melbourne, Victoria, Australia · Active not recruiting

  • Royal Melbourne Hospital (RMH)

    Parkville, Victoria, Australia · Active not recruiting

  • University Health Network

    Toronto, Canada · Recruiting

  • The Hospital for Sick Children

    Toronto, Canada · Active not recruiting

  • Hospital Saint-Louis - APHP

    Paris, France · Recruiting

  • Centre Hospitalier Universitaire (CHU) de Bordeaux

    Pessac, France · Recruiting

  • Centre Hospitalier Lyon Sud

    Pierre-Bénite, France · Recruiting

  • Institut Gustave Roussy-Gustave Roussy Cancer Center -DITEP

    Villejuif, France · Recruiting

  • Universitaetsklinikum Essen (AoR)

    Essen, Germany · Withdrawn

  • Universitaetsmedizin Greifswald

    Greifswald, Germany · Completed

  • Universitaetsmedizin Der Johannes

    Gutenberg, Germany · Recruiting

  • Universitaetsklinikum Hamburg-Eppendorf

    Hamburg, Germany · Recruiting

  • University of Leipzig

    Leipzig, Germany · Recruiting

  • Klinikum Nuernberg Nord

    Nuremberg, Germany · Completed

  • University Hospital Of Ulm, Universitatsklinikum Ulm

    Ulm, Baden-Wurttemberg, Germany · Recruiting

Showing 40 of 57 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.